Welcome to our dedicated page for SpyGlass Pharma SEC filings (Ticker: SGP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SpyGlass Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SpyGlass Pharma's regulatory disclosures and financial reporting.
A director of SpyGlass Pharma, Inc. filed an amended insider trading report updating how many shares are indirectly owned following the company’s initial public offering. The filing shows indirect beneficial ownership of 3,310,619 shares of common stock held through Vensana Capital I, L.P.
The amendment restates derivative holdings to reflect that shares of Series B, Series C-1, Series C-2 and Series D preferred stock, totaling 1,690,230, 548,067, 548,067 and 359,255 shares respectively, automatically converted on a one-for-one basis into common stock before the IPO closing.
SpyGlass Pharma, Inc. reported insider transactions involving entities associated with director and 10% owner Ali Behbahani on February 9, 2026. Several series of preferred stock automatically converted on a one-for-one basis into common stock immediately before the closing of the company’s initial public offering on that date.
The converted shares were held by New Enterprise Associates funds NEA 17 and NEA 16, for which Behbahani is a manager of the respective general partners. He disclaims beneficial ownership of portions in which he has no pecuniary interest. In addition, an NEA 17-related entity acquired 937,500 shares of common stock in an open‑market or private purchase at $16 per share, reported as indirect ownership.
SpyGlass Pharma, Inc. reported insider-related equity changes involving a 10% owner on February 9, 2026. Investment entities NEA 17 and NEA 16, which are the direct beneficial owners of the securities, had multiple series of preferred stock automatically convert on a one-for-one basis into common stock before the closing of SpyGlass Pharma’s initial public offering on February 9, 2026.
On the same date, an entity associated with NEA 17 indirectly purchased 937,500 shares of common stock at $16 per share. After these transactions, 6,035,038 shares of common stock were indirectly beneficially owned through NEA 17 and 1,357,263 shares through NEA 16, while the reporting person disclaims beneficial ownership of portions in which he has no pecuniary interest.
SpyGlass Pharma’s 10% holder Baskett Forest, through investment funds NEA 17 and NEA 16, reported multiple indirect acquisitions of common stock on February 9, 2026. Several series of preferred stock automatically converted into common stock on a one-for-one basis in connection with the company’s initial public offering.
In addition, an affiliated fund indirectly bought 937,500 shares of common stock at $16 per share, bringing its indirect common stock holdings reported in this filing to 6,035,038 shares, while another affiliated fund reported 1,357,263 indirectly held shares. Baskett Forest disclaims beneficial ownership of portions of these positions where there is no pecuniary interest.
New Enterprise Associates 17, L.P., a 10% owner of SpyGlass Pharma, Inc., reported several equity changes tied to the company’s initial public offering. On February 9, 2026, multiple series of preferred stock automatically converted on a one-for-one basis into common stock before the IPO closed.
These conversions increased NEA 17’s direct holdings to 5,097,538 shares of common stock. On the same date, NEA 17 also purchased 937,500 shares of common stock at $16 per share, bringing its directly held position to 6,035,038 common shares.
The securities are directly held by NEA 17 and indirectly by NEA Partners 17, L.P., NEA 17 GP, LLC, and specified individual managers, who disclaim beneficial ownership of portions in which they have no pecuniary interest.
SpyGlass Pharma, Inc. reported insider activity linked to investment fund New Enterprise Associates 17, L.P. (NEA 17), with Rick Yang as the Section 16 reporting person. On February 9, 2026, all Series B, Series C-1, Series C-2 and Series D preferred stock automatically converted on a one-for-one basis into the same number of common shares in connection with the company’s initial public offering.
On the same date, NEA 17 also reported an indirect open‑market or private purchase of 937,500 shares of common stock at $16 per share, bringing its indirectly held common stock position to 6,035,038 shares. The filing explains that NEA 17 is the direct beneficial owner and that Rick Yang disclaims beneficial ownership of any portion in which he has no pecuniary interest.
SpyGlass Pharma’s 10% owner Mohamad Makhzoumi reported IPO-related share activity on February 9, 2026. Investment entities associated with him converted multiple series of preferred stock into common stock on a one-for-one basis immediately before the company’s initial public offering.
The filing also shows an indirect open-market or private purchase of 937,500 shares of common stock at $16 per share, bringing related indirect holdings to 6,035,038 common shares under the NEA 17 structure. Additional indirect common shares are held through NEA 16 entities. Makhzoumi disclaims beneficial ownership of portions of these fund-held securities where he has no pecuniary interest.
SpyGlass Pharma’s Form 4 shows venture funds affiliated with Scott D. Sandell increasing their indirect common stock holdings around the company’s initial public offering. On February 9, 2026, multiple series of preferred stock automatically converted one-for-one into common shares before the IPO closing.
NEA 17-related entities ended with 6,035,038 shares of common stock held indirectly, including an open-market or private purchase of 937,500 shares at $16 per share. NEA 16-related entities held 1,357,263 common shares indirectly. The footnotes state Sandell disclaims beneficial ownership of portions of these fund-held securities in which he has no pecuniary interest.
SpyGlass Pharma 10% owner Chang Carmen, through New Enterprise Associates funds, reported multiple indirect transactions on February 9, 2026. All Series A, B, C-1, C-2 and D preferred stock automatically converted on a one-for-one basis into common stock in connection with SpyGlass Pharma’s initial public offering. In addition, an affiliated fund indirectly purchased 937,500 shares of common stock at $16 per share. The filing notes that Carmen disclaims beneficial ownership of portions of NEA 16 and NEA 17 holdings in which there is no pecuniary interest.
SpyGlass Pharma, Inc. reported that investment entities associated with 10% owner Paul Edward Walker indirectly acquired common stock around the company’s initial public offering. On February 9, 2026, all outstanding preferred stock series automatically converted into common stock on a one-for-one basis before the IPO closing, creating large indirect common holdings for New Enterprise Associates funds.
On the same date, an entity linked to Walker also indirectly purchased 937,500 shares of common stock at $16 per share, bringing that entity’s indirect common holdings to 6,035,038 shares, as referenced in Note 2. Separate entities referenced in Note 3 indirectly held 1,357,263 shares of common stock after related conversions.